BIOAPartnership•prnewswire•
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
Sentiment:Positive (70)
Summary
STOCKHOLM, Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new treatment combining BioArctic's proprietary...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 26, 2025 by prnewswire